David Shifteh
6PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Nov 13, 2025
A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC.Mark Spivak, Moshe Pahmer, Dorna Delrahimnia
|Sep 13, 2025
Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer.Ethan Abizadeh, Eli Berglas, Aaron Abizadeh
|Aug 28, 2025
Current and Emerging Therapies for Targeting Protein Arginine Methyltransferases (PRMTs) in Cancer.Adriana Kaganovski, Bayle Smith-Salzberg, Hadar K Shimshon
|Aug 27, 2025
PRMT5 Inhibition as a Potential Strategy for KRAS Mutant CRC: Downstream Mediators of the PRMT5-KRAS Crosstalk.Mark Spivak, Moshe Pahmer, Dorna Delrahimnia
|Dec 08, 2020
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.Tzuriel Sapir, David Shifteh, Moshe Pahmer
|Aug 01, 2020
Protein Arginine Methyltransferase 5 as a Therapeutic Target for <i>KRAS</i> Mutated Colorectal Cancer.David Shifteh, Tzuriel Sapir, Moshe Pahmer
Pageof 1
